This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza vaccination | 579 |
public health | 269 |
vaccination coverage | 240 |
influenza vaccine | 213 |
vaccination uptake | 188 |
health care | 183 |
seasonal influenza | 179 |
united states | 158 |
infectious diseases | 157 |
adverse events | 137 |
immune response | 118 |
immune system | 111 |
immune responses | 88 |
vaccine uptake | 86 |
vaccination rates | 83 |
pandemic influenza | 83 |
care workers | 82 |
pregnant women | 80 |
infectious disease | 75 |
vaccination among | 73 |
vaccine safety | 66 |
healthcare workers | 65 |
hong kong | 64 |
multiple sclerosis | 64 |
pneumococcal vaccination | 63 |
high risk | 61 |
vaccine hesitancy | 56 |
vaccine failure | 56 |
vaccine coverage | 55 |
mmr vaccine | 55 |
vaccination status | 55 |
doc id | 55 |
advisory committee | 55 |
cord uid | 55 |
vaccination rate | 54 |
vaccination program | 52 |
disease control | 51 |
preventable diseases | 51 |
side effects | 47 |
risk groups | 47 |
eff ectiveness | 45 |
mumps virus | 45 |
adverse effects | 45 |
world health | 44 |
systematic review | 44 |
coverage rates | 44 |
vaccine development | 44 |
mumps vaccine | 43 |
live attenuated | 43 |
innate immune | 43 |
ms patients | 42 |
mandatory vaccination | 42 |
chronic disease | 40 |
coverage among | 40 |
vaccinated individuals | 39 |
maternal vaccination | 39 |
vaccine administration | 39 |
new zealand | 39 |
health organization | 38 |
caret pointing | 38 |
vaccination campaign | 38 |
vaccination training | 38 |
influenza virus | 37 |
flu vaccination | 37 |
modified live | 37 |
chronic diseases | 37 |
vaccine efficacy | 37 |
increased risk | 37 |
pneumococcal vaccine | 37 |
herd immunity | 37 |
maternal antibody | 36 |
adverse event | 36 |
rainbow trout | 36 |
risk perception | 36 |
general population | 35 |
antibody response | 34 |
antibody titers | 34 |
immunization practices | 34 |
clinical signs | 34 |
present study | 33 |
social norms | 33 |
bcg vaccination | 32 |
factors associated | 32 |
influenza pandemic | 32 |
human papillomavirus | 31 |
may also | 31 |
perceived risk | 30 |
vaccines may | 30 |
vaccination intention | 29 |
health authorities | 29 |
coverage rate | 29 |
respiratory tract | 29 |
vaccination may | 29 |
statistically significant | 28 |
get vaccinated | 28 |
canine distemper | 28 |
vaccination game | 28 |
virus vaccine | 28 |
vaccination policy | 27 |
live vaccines | 27 |
negative association | 27 |
influenza season | 27 |
anticipated regret | 27 |
multivariate analysis | 27 |
social media | 27 |
national immunization | 27 |
univariate analysis | 27 |
acute respiratory | 27 |
canine rabies | 27 |
yellow fever | 27 |
antibody levels | 27 |
following vaccination | 26 |
significant difference | 26 |
positive association | 26 |
smallpox vaccination | 26 |
influenza vaccines | 26 |
informed consent | 26 |
economic evaluation | 26 |
rabies virus | 26 |
disease outbreaks | 26 |
mmr vaccination | 26 |
european countries | 26 |
significant negative | 26 |
significant positive | 26 |
adverse reactions | 25 |
vaccination groups | 25 |
clinical trials | 25 |
rubella vaccine | 25 |
severe acute | 25 |
increase vaccination | 25 |
significantly higher | 25 |
mass vaccination | 25 |
autoimmune diseases | 25 |
current recommendation | 25 |
annual influenza | 25 |
risk group | 25 |
respiratory syndrome | 25 |
age group | 25 |
vaccination history | 24 |
immunization program | 24 |
aged years | 24 |
vaccine strain | 24 |
failure rate | 24 |
logistic regression | 24 |
risk factors | 24 |
type i | 24 |
vaccination strategies | 24 |
sample size | 23 |
age groups | 23 |
positively linked | 23 |
antibody responses | 23 |
new vaccines | 23 |
health services | 23 |
human rabies | 23 |
distemper virus | 23 |
previous studies | 23 |
mumps outbreaks | 23 |
vaccination programs | 22 |
mumps infection | 22 |
mobile medical | 22 |
emergency preparedness | 22 |
developing countries | 22 |
rabies control | 22 |
rabies vaccine | 22 |
children aged | 22 |
vaccination behaviours | 22 |
health professionals | 22 |
among pregnant | 22 |
thrombocytopenic purpura | 22 |
mumps outbreak | 22 |
united kingdom | 21 |
conjugate vaccine | 21 |
disease prevention | 21 |
vaccination strategy | 21 |
modifying therapies | 21 |
avian influenza | 21 |
general practitioners | 21 |
voluntary vaccination | 21 |
maternal antibodies | 21 |
correlation coefficient | 21 |
double caret | 21 |
virus infection | 21 |
medical records | 21 |
uptake among | 21 |
vaccination behavior | 20 |
one study | 20 |
negatively linked | 20 |
among health | 20 |
humoral immunity | 20 |
pneumococcal vaccinations | 20 |
relapse rate | 20 |
vaccination planning | 20 |
pointing upwards | 20 |
minimum vaccination | 20 |
vaccination campaigns | 20 |
level evidence | 20 |
antiviral treatment | 20 |
inactivated vaccines | 19 |
vaccine acceptance | 19 |
live virus | 19 |
among children | 19 |
medical teams | 19 |
eff ects | 19 |
reported vaccination | 19 |
resource allocation | 19 |
tetanus toxoid | 19 |
year later | 19 |
canine parvovirus | 19 |
nervous system | 19 |
domestic dog | 19 |
dog rabies | 19 |
response rate | 19 |
prevent infection | 19 |
clinical disease | 19 |
even though | 18 |
task force | 18 |
immunization schedule | 18 |
routine vaccination | 18 |
mandatory influenza | 18 |
vaccine effectiveness | 18 |
many countries | 18 |
immersion vaccination | 18 |
respiratory symptoms | 18 |
trout nalt | 18 |
ns relapse | 18 |
sectional study | 18 |
social dilemma | 18 |
general practice | 18 |
lupus erythematosus | 18 |
systemic lupus | 18 |
pointing downwards | 18 |
resistant strains | 18 |
vaccine adverse | 18 |
ms disease | 18 |
information system | 18 |
infectious agents | 17 |
new vaccine | 17 |
central nervous | 17 |
towards vaccination | 17 |
acellular pertussis | 17 |
second dose | 17 |
training program | 17 |
pharmacy students | 17 |
ns relapses | 17 |
maximum vaccination | 17 |
autoimmune disease | 17 |
attitudes towards | 17 |
core vaccines | 17 |
simultaneous vaccination | 17 |
fmd virus | 17 |
decision making | 17 |
chronic illness | 17 |
time scale | 17 |
among adults | 17 |
rheumatoid arthritis | 17 |
vaccination programmes | 17 |
routine immunization | 17 |
vaccination period | 17 |
nephrotic syndrome | 17 |
high vaccination | 17 |
disease management | 16 |
great britain | 16 |
risk perceptions | 16 |
smallpox vaccine | 16 |
never vaccinated | 16 |
virus vaccines | 16 |
working group | 16 |
controlled trial | 16 |
priority group | 16 |
control group | 16 |
literature review | 16 |
reported immunity | 16 |
highly vaccinated | 16 |
social marketing | 16 |
immunization programs | 16 |
news media | 16 |
vaccination cost | 16 |
control study | 16 |
previous season | 15 |
animal health | 15 |
vaccination schedules | 15 |
criminal sanctions | 15 |
two doses | 15 |
influenza immunization | 15 |
care providers | 15 |
sectional survey | 15 |
pneumococcal polysaccharide | 15 |
nasal vaccination | 15 |
haemophilus influenzae | 15 |
rabies vaccination | 15 |
class ii | 15 |
hpv vaccine | 15 |
health policy | 15 |
childhood vaccination | 15 |
among healthcare | 15 |
epidemic model | 15 |
vaccination schedule | 15 |
weeks later | 15 |
dog populations | 15 |
cervical cancer | 15 |
environmental factors | 15 |
will need | 15 |
health law | 15 |
pull pod | 15 |
factors influencing | 15 |
direct contact | 15 |
following influenza | 15 |
examples include | 14 |
odds ratios | 14 |
vaccinated groups | 14 |
authors declare | 14 |
risk assessment | 14 |
local time | 14 |
like illness | 14 |
health interventions | 14 |
dog vaccination | 14 |
rural areas | 14 |
communicable diseases | 14 |
primary health | 14 |
social networks | 14 |
vaccination compliance | 14 |
itp risk | 14 |
mortality rates | 14 |
new york | 14 |
treatment game | 14 |
adaptive immune | 14 |
income countries | 14 |
active immunization | 14 |
infected individuals | 14 |
cause disease | 14 |
vaccination decisions | 14 |
live vaccine | 14 |
inactivated influenza | 14 |
childhood immunization | 14 |
injection site | 14 |
memory cells | 14 |
among patients | 14 |
future studies | 14 |
immunization coverage | 14 |
infection control | 14 |
immunization policy | 14 |
higher vaccination | 14 |
people aged | 14 |
immune thrombocytopenic | 14 |
flu vaccine | 14 |
benefi ts | 14 |
infl uenza | 14 |
receive influenza | 14 |
young children | 14 |
pneumococcal vaccines | 14 |
measles vaccine | 14 |
may occur | 14 |
wild type | 14 |
feline calicivirus | 14 |
canine adenovirus | 14 |
healthy people | 14 |
missed opportunities | 14 |
education level | 14 |
total population | 13 |
preparedness plans | 13 |
time scales | 13 |
mucosal immune | 13 |
domestic dogs | 13 |
target groups | 13 |
future vaccination | 13 |
peripheral blood | 13 |
hbv vaccine | 13 |
global health | 13 |
disease burden | 13 |
concerns regarding | 13 |
two groups | 13 |
care personnel | 13 |
polio vaccine | 13 |
influenzae type | 13 |
attenuated ihnv | 13 |
general public | 13 |
may lead | 13 |
inactivated vaccine | 13 |
healthy individuals | 13 |
pertussis vaccination | 13 |
pet owners | 13 |
syndrome induced | 13 |
national health | 13 |
mouth disease | 13 |
two studies | 13 |
pneumococcal conjugate | 13 |
health service | 13 |
cellular immunity | 13 |
influenza infection | 13 |
vaccination behaviour | 13 |
rubella vaccination | 12 |
disease transmission | 12 |
per year | 12 |
lymphoid tissues | 12 |
immunodeficiency virus | 12 |
may cause | 12 |
health gains | 12 |
performed using | 12 |
maternally derived | 12 |
preparedness planning | 12 |
epidemiological studies | 12 |
valent pneumococcal | 12 |
bacille calmette | 12 |
social distancing | 12 |
low vaccination | 12 |
high levels | 12 |
vaccine responses | 12 |
neutralizing antibody | 12 |
humoral immune | 12 |
oncorhynchus mykiss | 12 |
risks associated | 12 |
vaccination decision | 12 |
national vaccine | 12 |
may result | 12 |
epidemic spreading | 12 |
vaccination group | 12 |
relative cost | 12 |
hpv vaccination | 12 |
respiratory viruses | 12 |
events associated | 12 |
healthcare professionals | 12 |
emerging infectious | 12 |
rabies deaths | 12 |
waning immunity | 12 |
pneumococcal disease | 12 |
game theory | 12 |
much higher | 12 |
update rule | 12 |
immune status | 12 |
time preference | 12 |
vaccination programme | 12 |
natural infection | 12 |
smallpox virus | 12 |
infectious hematopoietic | 12 |
tract disease | 12 |
hematopoietic necrosis | 12 |
vaccine designed | 11 |
recommended vaccines | 11 |
inactivated subunit | 11 |
virus infections | 11 |
type diabetes | 11 |
database isr | 11 |
varicella vaccine | 11 |
perceived benefits | 11 |
influenza vaccinations | 11 |
ex post | 11 |
mumps vaccines | 11 |
specific igg | 11 |
olfactory organ | 11 |
legal database | 11 |
attenuated vaccines | 11 |
young adults | 11 |
th century | 11 |
will become | 11 |
factors affecting | 11 |
clinical practice | 11 |
susceptible individuals | 11 |
community engagement | 11 |
event reporting | 11 |
become susceptible | 11 |
health officials | 11 |
swine influenza | 11 |
passive transfer | 11 |
eff ective | 11 |
european centre | 11 |
heuristic algorithm | 11 |
discount rate | 11 |
associated adverse | 11 |
pertussis vaccine | 11 |
reporting system | 11 |
measles vaccination | 11 |
cell responses | 11 |
common ors | 11 |
mediated immunity | 11 |
vaccinated group | 11 |
optic neuritis | 11 |
population size | 11 |
rates among | 11 |
severe adverse | 11 |
higher risk | 11 |
vaccine preventable | 11 |
hypersensitivity reactions | 11 |
nevo legal | 11 |
immunological response | 11 |
upper respiratory | 11 |
oral route | 11 |
recent years | 11 |
getting vaccinated | 11 |
swine flu | 11 |
vaccination recommendations | 11 |
nasal secretions | 11 |
policy makers | 11 |
vaccinated population | 11 |
multiple vaccines | 11 |
adverse reaction | 10 |
vaccine adjuvants | 10 |
elderly persons | 10 |
valtcheva mv | 10 |
vaccines used | 10 |
medical care | 10 |
cohort study | 10 |
multiple logistic | 10 |
confidence interval | 10 |
disease outbreak | 10 |
whole population | 10 |
vaccine strains | 10 |
case reports | 10 |
complex networks | 10 |
chronic obstructive | 10 |
ciotti jr | 10 |
diabetes mellitus | 10 |
childhood vaccines | 10 |
distemper vaccine | 10 |
jl vaccine | 10 |
lessons learned | 10 |
protective immunity | 10 |
young animals | 10 |
myopic update | 10 |
higher uptake | 10 |
weeks old | 10 |
incubation period | 10 |
barr virus | 10 |
vaccine available | 10 |
mumps cases | 10 |
bone marrow | 10 |
measles virus | 10 |
standard screening | 10 |
south korea | 10 |
child vaccination | 10 |
health outcomes | 10 |
parental autonomy | 10 |
persons aged | 10 |
traffic flow | 10 |
years old | 10 |
available online | 10 |
israeli ministry | 10 |
contracting influenza | 10 |
herpes zoster | 10 |
common cold | 10 |
antigen flu | 10 |
disseminated encephalomyelitis | 10 |
cross ah | 10 |
current study | 10 |
mixed reality | 10 |
common reason | 10 |
dendritic cells | 10 |
acute disseminated | 10 |
medical record | 10 |
vaccination guidelines | 10 |
infected cats | 10 |
administer vaccinations | 10 |
odds ratio | 10 |
flu vaccines | 10 |
contagious diseases | 10 |
study found | 10 |
vaccine cost | 10 |
statistical analysis | 10 |
push pull | 10 |
vaccine manufacturers | 10 |
towards influenza | 10 |
healthy adults | 10 |
low risk | 10 |
health behaviour | 10 |
national institute | 10 |
information systems | 10 |
safety concerns | 10 |
among adolescents | 10 |
hcw influenza | 10 |
asia syndrome | 10 |
respiratory disease | 10 |
human services | 10 |
post vaccination | 10 |
canarypox virus | 10 |
made available | 10 |
priority groups | 10 |
vaccines among | 9 |
resistant strain | 9 |
change model | 9 |
case patients | 9 |
hcw vaccination | 9 |
reported influenza | 9 |
among nurses | 9 |
global time | 9 |
first aid | 9 |
widely used | 9 |
bcg vaccine | 9 |
human beings | 9 |
antibody titer | 9 |
necrosis virus | 9 |
study population | 9 |
pulmonary disease | 9 |
positively associated | 9 |
jeryl lynn | 9 |
mean age | 9 |
mumps antibodies | 9 |
molecular mimicry | 9 |
first year | 9 |
vaccine supply | 9 |
vaccines available | 9 |
three years | 9 |
vaccination might | 9 |
regarding adverse | 9 |
lkt specific | 9 |
causes respiratory | 9 |
surveillance system | 9 |
validation sticker | 9 |
reproduction number | 9 |
patients taking | 9 |
canine hepatitis | 9 |
inflammatory cytokines | 9 |
entire population | 9 |
important role | 9 |
predisposing factors | 9 |
retrospective study | 9 |
health promotion | 9 |
behavioural change | 9 |
care staff | 9 |
high proportion | 9 |
study design | 9 |
canine vaccination | 9 |
among people | 9 |
animal models | 9 |
expanded program | 9 |
small animal | 9 |
immunization practice | 9 |
antibody interference | 9 |
neutralizing antibodies | 9 |
sociodemographic characteristics | 9 |
fatal disease | 9 |
lymph nodes | 9 |
american academy | 9 |
vaccine antigens | 9 |
vaccine doses | 9 |
several studies | 9 |
transmission dynamics | 9 |
small number | 9 |
important factor | 9 |
viral infection | 9 |
see table | 9 |
type ii | 9 |
reported cases | 9 |
events following | 9 |
drug administration | 9 |
vaccine induced | 9 |
regression analysis | 9 |
available data | 9 |
previously vaccinated | 9 |
study showed | 9 |
dimethyl fumarate | 9 |
factors related | 9 |
vaccine will | 9 |
preventable disease | 9 |
least one | 9 |
killed vaccines | 9 |
type iii | 9 |
regarding vaccination | 9 |
internal medicine | 9 |
south africa | 9 |
first vaccination | 9 |
knowledge score | 9 |
signs include | 9 |
recent study | 9 |
management information | 9 |
containing vaccine | 9 |
many years | 9 |
autoimmune inflammatory | 9 |
candidate vaccine | 9 |
resistance evolution | 9 |
significant differences | 9 |
prospective study | 9 |
mg kg | 9 |
longitudinal study | 9 |
regarding vaccine | 9 |
general recommendation | 9 |
lyme disease | 9 |
influenza viruses | 9 |
primary vaccine | 9 |
scientific evidence | 9 |
vaccine refusal | 9 |
influenza seasons | 9 |
total number | 9 |
smallpox case | 9 |
maternal immunity | 9 |
per million | 9 |
infectious canine | 9 |
japanese encephalitis | 9 |
years later | 9 |
immunization services | 8 |
matched case | 8 |
prescribing behaviour | 8 |
feline herpesvirus | 8 |
meningococcal disease | 8 |
polio eradication | 8 |
vaccination messages | 8 |
vaccination effectiveness | 8 |
relatively high | 8 |
streptococcus pneumoniae | 8 |
whooping cough | 8 |
demyelinating diseases | 8 |
adjusted life | 8 |
papillomavirus vaccination | 8 |
viral diseases | 8 |
qualitative research | 8 |
rabies vaccines | 8 |
control patients | 8 |
statistical analyses | 8 |
cell response | 8 |
predict vaccination | 8 |
vaccines containing | 8 |
bowel disease | 8 |
hcp recommendation | 8 |
family physicians | 8 |
another study | 8 |
may become | 8 |
naturally occurring | 8 |
infectious agent | 8 |
cause serious | 8 |
content analysis | 8 |
recommended group | 8 |
copyright holder | 8 |
immune thrombocytopenia | 8 |
labeled cells | 8 |
minimal risk | 8 |
retroactive treatment | 8 |
additional child | 8 |
zoster virus | 8 |
three studies | 8 |
sir model | 8 |
vaccination knowledge | 8 |
higher odds | 8 |
healthy children | 8 |
vaccination year | 8 |
vast majority | 8 |
adjuvant effect | 8 |
specific antibody | 8 |
immunological memory | 8 |
least weeks | 8 |
vaccine use | 8 |
health agencies | 8 |
children born | 8 |
demographic data | 8 |
granted medrxiv | 8 |
international license | 8 |
evolutionary game | 8 |
outbreak control | 8 |
ihnv vaccine | 8 |
study may | 8 |
human swine | 8 |
may help | 8 |
vaccination score | 8 |
vaccination protocols | 8 |
inflammatory syndrome | 8 |
viral infections | 8 |
game approach | 8 |
feline vaccine | 8 |
middle east | 8 |
best practices | 8 |
deaths per | 8 |
regarding ph | 8 |
routine childhood | 8 |
ethics committee | 8 |
safety issues | 8 |
health impact | 8 |
serum antibody | 8 |
following administration | 8 |
urban areas | 8 |
social services | 8 |
polysaccharide vaccine | 8 |
weekly report | 8 |
studies reported | 8 |
papilloma virus | 8 |
clinical symptoms | 8 |
passive immunity | 8 |
parenteral vaccination | 8 |
author funder | 8 |
vaccine antigen | 8 |
inflammatory bowel | 8 |
low levels | 8 |
attenuated mumps | 8 |
child allowance | 8 |
connective tissue | 8 |
contact persons | 8 |
push pod | 8 |
posted june | 8 |
feline panleukopenia | 8 |
effective method | 8 |
nineteenth century | 8 |
internal consistency | 8 |
imperfect vaccination | 8 |
vaccine advisory | 8 |
community health | 8 |
enveloped virus | 8 |
major reasons | 8 |
multivalent product | 8 |
mda titres | 8 |
control actions | 8 |
vaccines will | 8 |
well documented | 8 |
previous infection | 8 |
fixed point | 8 |
patients receiving | 8 |
transmission occurs | 8 |
child care | 8 |
varicella vaccination | 8 |
version posted | 8 |
north america | 8 |
vaccines immunother | 8 |
randomised controlled | 8 |
wild poliovirus | 8 |
smallpox epidemic | 8 |
merial ltd | 8 |
poliovirus vaccine | 8 |
parainfluenza virus | 8 |
vaccination efforts | 8 |
measles outbreak | 8 |
mediated immune | 8 |
care system | 8 |
disease incidence | 8 |
promote vaccination | 8 |
pediatric patients | 8 |
mainly due | 8 |
demographic characteristics | 8 |
variola virus | 8 |
influenza prevention | 8 |
molecular epidemiology | 8 |
study group | 8 |
risk associated | 8 |
vaccine may | 8 |
best practice | 8 |
developing world | 8 |
subunit vaccine | 8 |
significantly associated | 8 |
following year | 8 |
vaccination compared | 8 |
recovered agents | 8 |
vaccine administered | 8 |
respiratory infections | 8 |
specific disease | 8 |
conjugate vaccines | 8 |
laboratory diagnosis | 8 |
data collection | 8 |
among elderly | 8 |
one case | 8 |
influenza outbreak | 8 |
population will | 8 |
vaccinated populations | 8 |
easy access | 8 |
significantly lower | 8 |
personal health | 8 |
high coverage | 8 |
disease patients | 8 |
across countries | 8 |
limited number | 8 |
vaccine recipients | 8 |
natural exposure | 8 |
emphasis framing | 8 |
long term | 8 |
vaccination service | 7 |
oral polio | 7 |
significantly different | 7 |
population density | 7 |
vaccines administered | 7 |
thai patients | 7 |
cost eff | 7 |
intranasal vaccines | 7 |
aluminum salts | 7 |
measles elimination | 7 |
ethical issues | 7 |
among travellers | 7 |
recombinant vaccines | 7 |
school immunization | 7 |
noncore vaccines | 7 |
proactive vaccination | 7 |
study period | 7 |
adults aged | 7 |
unvaccinated children | 7 |
prior vaccination | 7 |
class i | 7 |
feline leukemia | 7 |
health bodies | 7 |
simultaneous administration | 7 |
become available | 7 |
mortality rate | 7 |
communication strategies | 7 |
tetanus vaccination | 7 |
vaccine promotion | 7 |
last years | 7 |
associated factors | 7 |
transmitted via | 7 |
sensitive strain | 7 |
mucosal vaccines | 7 |
framing theory | 7 |
five european | 7 |
controlling infectious | 7 |
vaccine among | 7 |
leukemia virus | 7 |
vaccinia virus | 7 |
vaccine based | 7 |
takes place | 7 |
dm patients | 7 |
prevent disease | 7 |
case fatality | 7 |
control reproduction | 7 |
vaccination arguments | 7 |
mmwr morbidity | 7 |
chronic fatigue | 7 |
qualitative studies | 7 |
continuously vaccinated | 7 |
veterinary profession | 7 |
received ph | 7 |
combined measles | 7 |
active immunity | 7 |
vaccine dose | 7 |
influence maternal | 7 |
days post | 7 |
israeli sewage | 7 |
first time | 7 |
comorbid conditions | 7 |
vaccine manufacturer | 7 |
public trust | 7 |
disease surveillance | 7 |
may increase | 7 |
two years | 7 |
highly contagious | 7 |
initial vaccination | 7 |
unicef joint | 7 |
imm group | 7 |
emerging diseases | 7 |
lung disease | 7 |
younger age | 7 |
mannheimia haemolytica | 7 |
times higher | 7 |
confidence intervals | 7 |
gene expression | 7 |
subunit vaccines | 7 |
within days | 7 |
industrialised countries | 7 |
also demonstrated | 7 |
vaccination information | 7 |
philosophical exemptions | 7 |
two cases | 7 |
internal fixed | 7 |
flu vaccinations | 7 |
circulating antibody | 7 |
virus challenge | 7 |
practice staff | 7 |
new public | 7 |
adenovirus type | 7 |
travel health | 7 |
discrete resources | 7 |
significant risk | 7 |
college students | 7 |
celiac disease | 7 |
vaccination within | 7 |
tetanus toxoids | 7 |
regarding influenza | 7 |
children program | 7 |
among european | 7 |
mucosal immunity | 7 |
joint reporting | 7 |
st century | 7 |
national vaccination | 7 |
risk populations | 7 |
preventive services | 7 |
system may | 7 |
free vaccine | 7 |
administer vaccines | 7 |
treatment efficacy | 7 |
southern africa | 7 |
first vaccine | 7 |
many infectious | 7 |
social affairs | 7 |
mortality weekly | 7 |
care settings | 7 |
recombinant hepatitis | 7 |
attitudes toward | 7 |
adjuvanted vaccine | 7 |
surveillance data | 7 |
site sarcomas | 7 |
current vaccination | 7 |
parent study | 7 |
three different | 7 |
different types | 7 |
effective vaccination | 7 |
vaccines must | 7 |
cases per | 7 |
gulf war | 7 |
usual source | 7 |
obstructive pulmonary | 7 |
smallpox attack | 7 |
may even | 7 |
vaccine quality | 7 |
postexposure vaccination | 7 |
vaccination route | 7 |
adult immunization | 7 |
humoral response | 7 |
higher incidence | 7 |
new technologies | 7 |
racing greyhounds | 7 |
life expectancy | 7 |
may reflect | 7 |
aid certificate | 7 |
two items | 7 |
people may | 7 |
frequently reported | 7 |
increasing vaccination | 7 |
vaccination scores | 7 |
intranasal vaccine | 7 |
infection risk | 7 |
glatiramer acetate | 7 |
patients aged | 7 |
warp speed | 7 |
fold increase | 7 |
significantly increased | 7 |
risk communication | 7 |
medical team | 7 |
health system | 7 |
fully vaccinated | 7 |
population structure | 7 |
reporting form | 7 |
close contact | 7 |
vaccination using | 7 |
mandatory opv | 7 |
herpesvirus i | 7 |
adjusted odds | 7 |
potentially fatal | 7 |
risk factor | 7 |
immunosuppressive treatment | 7 |
tissue disease | 7 |
vaccine recommendations | 7 |
cellular immune | 7 |
specific groups | 7 |
real time | 7 |
influenza among | 7 |
less likely | 7 |
associated lymphoid | 7 |
specific vaccine | 7 |
vaccine allocation | 7 |
actual vaccination | 7 |
cat households | 7 |
supreme court | 7 |
respiratory infection | 7 |
multiplex networks | 7 |
previous vaccination | 7 |
vaccine delivery | 7 |
third dose | 7 |
iii hypersensitivity | 7 |
vaccinated animal | 7 |
continuous variables | 7 |
adolescents aged | 7 |
cognitive determinants | 7 |
immunization status | 7 |
specific iga | 6 |
post provision | 6 |
epidemiologic evidence | 6 |
case report | 6 |
response rates | 6 |
mixed population | 6 |
million population | 6 |
confer protection | 6 |
mathematical model | 6 |
attenuated virus | 6 |
scheduling model | 6 |
vaccination games | 6 |
relapsing ms | 6 |
widespread use | 6 |
diphtheria toxoid | 6 |
incidence density | 6 |
test designed | 6 |
increase influenza | 6 |
prevent common | 6 |
maximum resources | 6 |
immunization information | 6 |
two major | 6 |
health belief | 6 |
common reasons | 6 |
regular exercise | 6 |
derived antibody | 6 |
zealand newspapers | 6 |
newly vaccinated | 6 |
hospital association | 6 |
combination vaccines | 6 |
case study | 6 |
among hcws | 6 |
plasma cells | 6 |
syncytial virus | 6 |
vaccine product | 6 |
lower coverage | 6 |
currently recommended | 6 |
family members | 6 |
vaccination routes | 6 |
median age | 6 |
genetic material | 6 |
operation warp | 6 |
influenza immunisation | 6 |
months later | 6 |
health centers | 6 |
recall response | 6 |
epidemic season | 6 |
sarcoma task | 6 |
serious disease | 6 |
vaccination movement | 6 |
national institutes | 6 |
previous study | 6 |
mumps vaccination | 6 |
challenge studies | 6 |
second vaccination | 6 |
killed virus | 6 |
epidemiological data | 6 |
provided free | 6 |
became available | 6 |
stated previously | 6 |
mumps immunity | 6 |
exact test | 6 |
will help | 6 |
among high | 6 |
immunization survey | 6 |
varicella zoster | 6 |
care facilities | 6 |
vaccine types | 6 |
novel influenza | 6 |
older adults | 6 |
interferon group | 6 |
relapse rates | 6 |
final year | 6 |
medical conditions | 6 |
overall vaccination | 6 |
fall within | 6 |
israeli law | 6 |
infected animals | 6 |
invasive pneumococcal | 6 |
potential adverse | 6 |
clinical manifestations | 6 |
rabies diagnosis | 6 |
two consecutive | 6 |
regulatory agency | 6 |
bullous pemphigoid | 6 |
respiratory syncytial | 6 |
veterinary vaccines | 6 |
good health | 6 |
recent mumps | 6 |
potential impact | 6 |
anthrax vaccine | 6 |
oil emulsions | 6 |
smallpox cases | 6 |
certain breeds | 6 |
mandatory vaccinations | 6 |
felv vaccine | 6 |
associated sarcomas | 6 |
may develop | 6 |
low uptake | 6 |
population health | 6 |
transgenic alfalfa | 6 |
detect antibody | 6 |
compulsory vaccination | 6 |
year period | 6 |
immunization registries | 6 |
control calves | 6 |
individuals may | 6 |
also occurs | 6 |
specific antibodies | 6 |
health authority | 6 |
one vaccine | 6 |
transverse myelitis | 6 |
review board | 6 |
igg antibodies | 6 |
antibody titres | 6 |
consecutive influenza | 6 |
proper purpose | 6 |
human factors | 6 |
epidemiological study | 6 |
program information | 6 |
viral vaccines | 6 |
secondary vaccine | 6 |
several reports | 6 |
global perspective | 6 |
significant treatment | 6 |
others may | 6 |
attitude toward | 6 |
saharan africa | 6 |
helicobacter pylori | 6 |
proposed methodology | 6 |
diabetes center | 6 |
data analysis | 6 |
health concern | 6 |
young adult | 6 |
core vaccine | 6 |
may exist | 6 |
injection vaccination | 6 |
future research | 6 |
health status | 6 |
immunization requirements | 6 |
first several | 6 |
practice guideline | 6 |
safety datalink | 6 |
legal center | 6 |
vaccination services | 6 |
louis pasteur | 6 |
increased association | 6 |
associated feline | 6 |
immersion vaccines | 6 |
last vaccine | 6 |
vaccine products | 6 |
bite injuries | 6 |
health beliefs | 6 |
viral antigens | 6 |
smallpox eradication | 6 |
blood lymphocytes | 6 |
measles cases | 6 |
widespread vaccination | 6 |
vaccination acceptance | 6 |
evidence suggests | 6 |
following immunization | 6 |
oral vaccination | 6 |
regarding seasonal | 6 |
bacillus calmette | 6 |
recall bias | 6 |
human behavior | 6 |
particular vaccine | 6 |
term protection | 6 |
studies showed | 6 |
recent outbreaks | 6 |
smallpox outbreak | 6 |
individuals become | 6 |
vaccine type | 6 |
older people | 6 |
lymphoid tissue | 6 |
limited destinations | 6 |
vaccination amongst | 6 |
western countries | 6 |
education framework | 6 |
relatively low | 6 |
fip virus | 6 |
following mmr | 6 |
statistical significance | 6 |
renal disease | 6 |
hpv vaccines | 6 |
feline core | 6 |
primary care | 6 |
residual virulence | 6 |
inflammatory responses | 6 |
target group | 6 |
epidemic outbreak | 6 |
one year | 6 |
game model | 6 |
several hours | 6 |
inpatient nurses | 6 |
spreading process | 6 |
currently available | 6 |
adult dogs | 6 |
race ethnicity | 6 |
primary healthcare | 6 |
perceived self | 6 |
private sector | 6 |
within years | 6 |
constitutional right | 6 |
veterinary practice | 6 |
congenital rubella | 6 |
will also | 6 |
first smallpox | 6 |
literature search | 6 |
disease may | 6 |
following symbols | 6 |
group vs | 6 |
vaccinate puppies | 6 |
hi titers | 6 |
coronavirus disease | 6 |
media stories | 6 |
historical data | 6 |
behaviour change | 6 |
antiviral immune | 6 |
human papilloma | 6 |
kittens may | 6 |
virus vaccination | 6 |
epidemiologic studies | 6 |
maternal vaccine | 6 |
lower vaccine | 6 |
working adults | 6 |
unvaccinated individuals | 6 |
year olds | 6 |
fiv antibody | 6 |
low compliance | 6 |
treatment cost | 6 |
pandemic infl | 6 |
toxoid vaccine | 6 |
media reports | 6 |
hiv aids | 6 |
compliance rates | 6 |
zoonotic disease | 6 |
seasonal flu | 6 |
feline immunodeficiency | 6 |
also known | 6 |
aged months | 6 |
older age | 6 |
korea centers | 6 |
vaccination alone | 6 |
vaccinated fish | 6 |
long time | 6 |
sir epidemic | 6 |
vaccinated hcws | 6 |
immunization safety | 6 |
high level | 6 |
measles mumps | 6 |
high prevalence | 6 |
health communication | 6 |
respiratory virus | 6 |
health doi | 6 |
bladder cancer | 6 |
pharmacy student | 6 |
game structure | 6 |
mucosal vaccination | 6 |
american indian | 6 |
planned behaviour | 6 |
ethical aspects | 6 |
immunization rates | 6 |
i hypersensitivity | 6 |
world war | 6 |
centered design | 6 |
i vaccine | 6 |
systematic reviews | 6 |
etiological agent | 6 |
many studies | 6 |
recombinant rabies | 6 |
screening test | 6 |
significance level | 6 |
american association | 6 |
mumps rubella | 6 |
time interaction | 6 |
toward influenza | 6 |
feline viral | 6 |
large number | 6 |
vaccination sites | 6 |
fatality rate | 6 |
square test | 6 |
previously described | 6 |
innate immunity | 6 |
control measures | 6 |
strategy update | 6 |
current vaccine | 6 |
every year | 6 |
local inflammation | 6 |
sensitivity analysis | 6 |
vaccinated patients | 6 |
vaccination responses | 6 |
remained suboptimal | 6 |
control efforts | 5 |
individual rights | 5 |
genetic predisposition | 5 |
joanna briggs | 5 |
future covid | 5 |
quality control | 5 |
calves fed | 5 |
within hours | 5 |
vaccination interview | 5 |
polymerase chain | 5 |
similar response | 5 |
time step | 5 |
practice nurses | 5 |
role play | 5 |
child health | 5 |
two months | 5 |
risk sociodemographic | 5 |
developing immune | 5 |
vaccination advocates | 5 |
seven studies | 5 |
vaccine research | 5 |
hospital records | 5 |
major histocompatibility | 5 |
nationally representative | 5 |
dilemma situation | 5 |
social influence | 5 |
actual disease | 5 |
evidence regarding | 5 |
vaccinated individual | 5 |
simply stated | 5 |
mortality among | 5 |
hemagglutination inhibition | 5 |
published literature | 5 |
healthcare worker | 5 |
recommended vaccinations | 5 |
yearly revaccination | 5 |
influenza pandemics | 5 |
idiopathic nephrotic | 5 |
effective intervention | 5 |
single vaccination | 5 |
system demyelinating | 5 |
sore throat | 5 |
immune function | 5 |
information spreading | 5 |
strongly associated | 5 |
health departments | 5 |
clear springs | 5 |
risk population | 5 |
cell epitopes | 5 |
increased incidence | 5 |
past experience | 5 |
two distinct | 5 |
adalla legal | 5 |
feline cd | 5 |
community protection | 5 |
vaccine failures | 5 |
commercially available | 5 |
two types | 5 |
feline patients | 5 |
smallpox patient | 5 |
educational campaigns | 5 |
based primarily | 5 |
broad range | 5 |
last pandemic | 5 |
infective cases | 5 |
knowledge scores | 5 |
native lkt | 5 |
pharmacy practice | 5 |
igg labeled | 5 |
measles infection | 5 |
limited resources | 5 |
vaccine components | 5 |
annual report | 5 |
cell types | 5 |
limited data | 5 |
ocrelizumab group | 5 |
typhoid fever | 5 |
readily transmissible | 5 |
earlier age | 5 |
among young | 5 |
may therefore | 5 |
human immunodeficiency | 5 |
receiving vaccination | 5 |
allocation problem | 5 |
epidemic outbreaks | 5 |
data available | 5 |
baseline scenario | 5 |
care setting | 5 |
iscom vaccines | 5 |
early life | 5 |
future influenza | 5 |
evolutionary process | 5 |
adult cats | 5 |
adult patients | 5 |
new south | 5 |
feline practitioners | 5 |
feline infectious | 5 |
antigen presenting | 5 |
rheumatic diseases | 5 |
also found | 5 |
likert scale | 5 |
well established | 5 |
refuse vaccination | 5 |
rotavirus vaccination | 5 |
diseases surveillance | 5 |
veterinary biologics | 5 |
key role | 5 |
justice arbel | 5 |
id validation | 5 |
infected individual | 5 |
university hospital | 5 |
modern vaccines | 5 |
rural tanzania | 5 |
human dignity | 5 |
receive ph | 5 |
maternal immunization | 5 |
hospital visit | 5 |
teaching hospital | 5 |
mass vaccinations | 5 |
elderly dependency | 5 |
hbv vaccines | 5 |
sterile immunity | 5 |
immunosuppressive treatments | 5 |
responses may | 5 |
household contacts | 5 |
studies suggest | 5 |
lymphocytes expressing | 5 |
categorical variables | 5 |
may need | 5 |
challenge experiments | 5 |
autoimmune response | 5 |
natural disease | 5 |
nasal innate | 5 |
antiphospholipid syndrome | 5 |
histocompatibility complex | 5 |
disease caused | 5 |
australian newspapers | 5 |
vaccine containing | 5 |
primary immune | 5 |
attitudes among | 5 |
treatment games | 5 |
safety review | 5 |
control groups | 5 |
different risk | 5 |
states immunization | 5 |
necrosis factor | 5 |
rotavirus vaccine | 5 |
effective vaccines | 5 |
pet owner | 5 |
high incidence | 5 |
may reduce | 5 |
post treatment | 5 |
human disease | 5 |
positive attitude | 5 |
conspiracy theories | 5 |
type virus | 5 |
microsoft excel | 5 |
controlled study | 5 |
opportunistic infections | 5 |
medical research | 5 |
commercial vaccine | 5 |
advisory panel | 5 |
vaccine trial | 5 |
although many | 5 |
emptive vaccination | 5 |
took place | 5 |
deliberate release | 5 |
type iv | 5 |
fatality rates | 5 |
high quality | 5 |
remain unvaccinated | 5 |
severe disease | 5 |
control studies | 5 |
emergency department | 5 |
numerical simulations | 5 |
distancing measures | 5 |
translational research | 5 |
age years | 5 |
acceptance among | 5 |
survival rate | 5 |
patient contact | 5 |
determine whether | 5 |
global eradication | 5 |
adjuvant vaccines | 5 |
virus genotype | 5 |
childhood diseases | 5 |
protective effect | 5 |
family physician | 5 |
immunity induced | 5 |
early detection | 5 |
elisa test | 5 |
personal vulnerability | 5 |
vaccinated agents | 5 |
diff erent | 5 |
immune cells | 5 |
mass media | 5 |
immunocompromised patients | 5 |
cell lines | 5 |
amino acid | 5 |
repeat vaccination | 5 |
empirical studies | 5 |
viral load | 5 |
basic law | 5 |
hospital das | 5 |
expressing surface | 5 |
animals vaccinated | 5 |
aluminum hydroxide | 5 |
risk benefit | 5 |
time pcr | 5 |
final manuscript | 5 |
making process | 5 |
antiviral immunity | 5 |
administered vaccinations | 5 |
second vaccine | 5 |
regional bodies | 5 |
western australia | 5 |
vaccination site | 5 |
induced antibodies | 5 |
free influenza | 5 |
disease among | 5 |
results suggest | 5 |
resources scenario | 5 |
us adults | 5 |
preventive health | 5 |
received influenza | 5 |
higher percentage | 5 |
old children | 5 |
induce autoimmunity | 5 |
hispanic black | 5 |
decreased risk | 5 |
baseline assessment | 5 |
published studies | 5 |
macrophagic myofasciitis | 5 |
routine use | 5 |
recombinant vaccine | 5 |
assessed using | 5 |
related factors | 5 |
traditional media | 5 |
serious illness | 5 |
public funding | 5 |
eighteenth century | 5 |
rabies elimination | 5 |
inactivated vaccination | 5 |
allergic reactions | 5 |
inclusion criteria | 5 |
mg day | 5 |
developed countries | 5 |
international health | 5 |
current evidence | 5 |
cell culture | 5 |
blood samples | 5 |
individual vaccination | 5 |
sectional surveys | 5 |
deterministic allocation | 5 |
administered subcutaneously | 5 |
agent i | 5 |
vaccination must | 5 |
might also | 5 |
live bacterin | 5 |
kong chinese | 5 |
vaccinees agreed | 5 |
western europe | 5 |
antigen delivery | 5 |
latent variable | 5 |
received two | 5 |
flu infections | 5 |
dog population | 5 |
susceptible individual | 5 |
national survey | 5 |
briggs institute | 5 |
vaccine within | 5 |
epidemic dynamics | 5 |
infringing intervention | 5 |
teaching team | 5 |
clinical mumps | 5 |
ages years | 5 |
pandemic vaccine | 5 |
medical sciences | 5 |
taking ph | 5 |
th cells | 5 |
factors including | 5 |
canine core | 5 |
rubella syndrome | 5 |
healthcare providers | 5 |
justice barak | 5 |
every months | 5 |
south wales | 5 |
multiple vaccination | 5 |
become infected | 5 |
canine parainfluenza | 5 |
based cross | 5 |
mononuclear cells | 5 |
nasal iga | 5 |
preventing influenza | 5 |
mumps viruses | 5 |
uptake strategy | 5 |
greyhound industry | 5 |
animal hospital | 5 |
available vaccines | 5 |
large proportion | 5 |
first days | 5 |
million people | 5 |
provide protection | 5 |
vaccine viruses | 5 |
breast implants | 5 |
new challenges | 5 |
may induce | 5 |
novel vaccine | 5 |
supplementary material | 5 |
relatively stable | 5 |
european union | 5 |
test result | 5 |
rabies prevention | 5 |
extensive vaccination | 5 |
hcj adalla | 5 |
declining vaccination | 5 |
imm groups | 5 |
south america | 5 |
vaccination also | 5 |
vaccinations among | 5 |
epidemic spread | 5 |
mucosal surface | 5 |
get infected | 5 |
among hospital | 5 |
animal care | 5 |
often fatal | 5 |
multiple discrete | 5 |
several days | 5 |
section addressed | 5 |
vaccines remain | 5 |
pediatric infectious | 5 |
positively framed | 5 |
childhood vaccine | 5 |
chain reaction | 5 |
animals may | 5 |
influenza epidemics | 5 |
polio vaccines | 5 |
structural equation | 5 |
vaccine availability | 5 |
primary vaccination | 5 |
real world | 5 |
tumor necrosis | 5 |
within two | 5 |
recent studies | 5 |
serum antibodies | 5 |
groups compared | 5 |
pharmacy schools | 5 |
immunization system | 5 |
behavioral influence | 5 |
less frequently | 5 |
government intervention | 5 |
cell mediated | 5 |
ae versus | 5 |
design thinking | 5 |
infectious peritonitis | 5 |
short term | 5 |
parental care | 5 |
industrialised world | 5 |
influencing maternal | 5 |
serious adverse | 5 |
vaccine production | 5 |
less common | 5 |
attack rate | 5 |
quality improvement | 5 |
developmental disorder | 5 |
professional responsibility | 5 |
immunization uptake | 5 |
mlv vaccines | 5 |
free networks | 5 |
perceived risks | 5 |
months post | 5 |
low coverage | 5 |
phase iii | 5 |
mandatory annual | 5 |
pasteur institute | 5 |
tertiary care | 5 |
los angeles | 5 |
flu season | 5 |
strategy will | 5 |
toward vaccination | 5 |
theoretical framework | 5 |
strong predictor | 5 |
veterinary community | 5 |
health locus | 5 |
vaccine distribution | 5 |
immunologic memory | 5 |
near future | 5 |
immunopreventable diseases | 5 |
better understand | 5 |
highest level | 5 |
small pox | 5 |
around vaccine | 5 |
black race | 5 |
times greater | 5 |
infection may | 5 |
preventing disease | 5 |
three papers | 5 |
effective vaccine | 5 |
dependency ratio | 5 |
first generation | 5 |
show clinical | 5 |
vaccinated agent | 5 |
country profiles | 5 |
two decades | 5 |
circulating strains | 5 |
selection bias | 5 |
health organisation | 5 |
position paper | 5 |
much lower | 5 |
children younger | 5 |
presenting cells | 5 |
social learning | 5 |
time since | 5 |
american animal | 5 |
pattern recognition | 5 |
joseon dynasty | 5 |
many vaccines | 5 |
randomly selected | 5 |
epidemiological evidence | 5 |
human decision | 5 |
medical technology | 5 |
population level | 5 |
economic evaluations | 5 |
vaccination dynamics | 5 |
protective levels | 5 |
main reason | 5 |
environmental conditions | 5 |
emergency response | 5 |
observational study | 5 |
economic development | 5 |
ethical guidelines | 5 |
vaccination influenza | 5 |
human body | 5 |
outbreak among | 5 |
healthcare personnel | 5 |
addressing vaccine | 5 |
antibodies directed | 5 |
selected vaccines | 5 |
mumps antibody | 5 |
many reasons | 5 |
unvaccinated people | 5 |
disease will | 5 |
purified subunit | 5 |
antibody production | 5 |
fever vaccination | 5 |
skill competency | 5 |
respiratory droplets | 5 |
vaccines including | 5 |
short time | 5 |
table shows | 5 |
include pyrexia | 5 |
health crisis | 5 |
patients treated | 5 |
disease spreading | 5 |
strains may | 5 |
urban setting | 5 |
hypersensitivity reaction | 5 |
health emergencies | 5 |
adalah case | 5 |
limiting disease | 5 |
idiopathic thrombocytopenic | 5 |
rapid diagnosis | 5 |
comprehensive review | 5 |
polio outbreak | 5 |
human rights | 5 |
initiation day | 5 |
fatigue syndrome | 5 |
studies using | 5 |
inactivated poliovirus | 5 |
discrete resource | 5 |
outpatient clinics | 5 |
farmed fish | 5 |
alfalfa expressing | 5 |
reported following | 5 |
health practice | 5 |
regression model | 4 |
bordetella bronchiseptica | 4 |
also include | 4 |
bluetongue virus | 4 |
health interview | 4 |
circulating muv | 4 |
term follow | 4 |
containing vaccines | 4 |
young stock | 4 |
susceptible hosts | 4 |
accept vaccination | 4 |
multiple cell | 4 |
included studies | 4 |
related genes | 4 |
theptarin hospital | 4 |
vaccination initiation | 4 |
old boy | 4 |
fully understood | 4 |
getting infected | 4 |
economic impact | 4 |
original tpb | 4 |
septicemia virus | 4 |
limitation clause | 4 |
specific memory | 4 |
pervasive developmental | 4 |
promote compliance | 4 |
first dose | 4 |
like receptor | 4 |
information factors | 4 |
veterinary medicines | 4 |
policy development | 4 |
successful vaccination | 4 |
high school | 4 |
mean survival | 4 |
vaccination records | 4 |
target populations | 4 |
inactivated polio | 4 |
public decision | 4 |
field approximation | 4 |
expanded vaccination | 4 |
nasopharyngeal lymphoid | 4 |
alemtuzumab treatment | 4 |
limited vaccine | 4 |
west africa | 4 |
safety studies | 4 |
persian gulf | 4 |
media messages | 4 |
may fail | 4 |
multivalent vaccines | 4 |
occurring within | 4 |
health ordinance | 4 |
epidemic starts | 4 |
news reports | 4 |
rabies surveillance | 4 |
hospital medical | 4 |
allergic reaction | 4 |
induced lkt | 4 |
initial series | 4 |
lacking influenza | 4 |
better health | 4 |
distemper vaccination | 4 |
belief model | 4 |
treating physicians | 4 |
das clinicas | 4 |
time period | 4 |
effective immune | 4 |
several infectious | 4 |
closely related | 4 |
potential exposure | 4 |
human immune | 4 |
may prevent | 4 |
comorbidity index | 4 |
professional organizations | 4 |
telephone surveys | 4 |
latin word | 4 |
african countries | 4 |
also important | 4 |
mlv canine | 4 |
routine vaccinations | 4 |
antibiotic resistance | 4 |
susceptible animals | 4 |
million children | 4 |
vaccine interference | 4 |
antiviral resistance | 4 |
human herpesvirus | 4 |
individual decisions | 4 |
serious clinical | 4 |
surface antigen | 4 |
disease risk | 4 |
among us | 4 |
two countries | 4 |
saudi arabia | 4 |
field studies | 4 |
high titres | 4 |
varied considerably | 4 |
immunity eff | 4 |
causes upper | 4 |
amongst gps | 4 |
improve vaccination | 4 |
disease threat | 4 |
confounding variables | 4 |
work loss | 4 |
vaccine compared | 4 |
vaccination teams | 4 |
across different | 4 |
three consecutive | 4 |
surface igm | 4 |
subsequent use | 4 |
studies indicate | 4 |
science research | 4 |
many pathogens | 4 |
findings suggest | 4 |
bite victims | 4 |
diabetes care | 4 |
mda may | 4 |
costeff ectiveness | 4 |
first weeks | 4 |
controlled clinical | 4 |
corticosteroids concurrently | 4 |
imitation dynamics | 4 |
clinical studies | 4 |
multiple vaccine | 4 |
vaccinated calves | 4 |
alaska native | 4 |
edward jenner | 4 |
live oral | 4 |
vaccinations varied | 4 |
hesitancy among | 4 |
population sizes | 4 |
hajj pilgrims | 4 |
reproduction numbers | 4 |
specific vaccines | 4 |
health assembly | 4 |
local area | 4 |
years ago | 4 |
complete remission | 4 |
vaccine protects | 4 |
studies included | 4 |
adaptive immunity | 4 |
canine infectious | 4 |
indirect costs | 4 |
recommend vaccination | 4 |
pet animals | 4 |
confirmed cases | 4 |
contagious disease | 4 |
universal vaccination | 4 |
hub nodes | 4 |
systemic antibody | 4 |
vaccine used | 4 |
towards seasonal | 4 |
surveillance systems | 4 |
two different | 4 |
days prior | 4 |
effect size | 4 |
following hepatitis | 4 |
th annual | 4 |
overcome maternal | 4 |
acquired immune | 4 |
states department | 4 |
school year | 4 |
health effects | 4 |
social science | 4 |
average age | 4 |
national policy | 4 |
racial ethnic | 4 |
itp occurrence | 4 |
vaccine developed | 4 |
acquired immunity | 4 |
unvaccinated child | 4 |
products containing | 4 |
administering vaccines | 4 |
canine vaccine | 4 |
aged children | 4 |
million deaths | 4 |
causal relationship | 4 |
cpv antibody | 4 |
present job | 4 |
nasal epithelium | 4 |
right thoracic | 4 |
important part | 4 |
based adjuvants | 4 |
mucosal surfaces | 4 |
appropriate response | 4 |
market mechanisms | 4 |
made possible | 4 |
study included | 4 |
mmr measles | 4 |
vaccinees thought | 4 |
case per | 4 |
vgg recognises | 4 |
better understanding | 4 |
studies support | 4 |
viral transmission | 4 |
studies conducted | 4 |
feline vaccines | 4 |
healthcare system | 4 |
selected local | 4 |
prevent cervical | 4 |
health benefits | 4 |
cells via | 4 |
mandatory immunization | 4 |
global vaccine | 4 |
two weeks | 4 |
mlv cdv | 4 |
attenuated viruses | 4 |
medical treatment | 4 |
expression levels | 4 |
medical field | 4 |
first live | 4 |
dilemma game | 4 |
european travellers | 4 |
immunisation coverage | 4 |
vaccination include | 4 |
vaccination season | 4 |
vaccine injury | 4 |
influenza epidemic | 4 |
measles vaccines | 4 |
animal studies | 4 |
received flu | 4 |
confers protection | 4 |
individual within | 4 |
previous reviews | 4 |
cowpox virus | 4 |
natural infections | 4 |
occurs within | 4 |
adjuvants activate | 4 |
received colostrum | 4 |
behavioral change | 4 |
several cases | 4 |
past years | 4 |
beliefs towards | 4 |
new vaccination | 4 |
human subjects | 4 |
serum albumin | 4 |
hospital hcws | 4 |
next generation | 4 |
cholera vaccine | 4 |
cats infected | 4 |
veterinary medicine | 4 |
within weeks | 4 |
preventive medicine | 4 |
israeli children | 4 |
model fit | 4 |
nash equilibrium | 4 |
conventional wisdom | 4 |
population living | 4 |
three days | 4 |
robert koch | 4 |
comparative study | 4 |
paramount importance | 4 |
simplified version | 4 |
second wave | 4 |
regarding rabies | 4 |
stem cell | 4 |
immunisation policy | 4 |
one item | 4 |
local pain | 4 |
quantitative studies | 4 |
quadrivalent hpv | 4 |
highly effective | 4 |
baseline survey | 4 |
authorities need | 4 |
university vaccination | 4 |
naturally infected | 4 |
ocular discharge | 4 |
temporally associated | 4 |
promotional efforts | 4 |
studied determinants | 4 |
elderly patients | 4 |
certain groups | 4 |
protective efficacy | 4 |
close contacts | 4 |
elderly people | 4 |
similar results | 4 |
intellectual content | 4 |
aluminum adjuvants | 4 |
shed light | 4 |
bacterial agent | 4 |
polyarteritis nodosa | 4 |
typically occurs | 4 |
pharyngeal lymphoid | 4 |
data suggest | 4 |
significant association | 4 |
vaccine candidates | 4 |
public security | 4 |
participating physicians | 4 |
low level | 4 |
feline enteric | 4 |
case series | 4 |
every years | 4 |
effective way | 4 |
net migration | 4 |
benefi cial | 4 |
clinical trial | 4 |
costs per | 4 |
adverse vaccine | 4 |
health systems | 4 |
study reported | 4 |
per district | 4 |
underlying disease | 4 |
daly burden | 4 |
patient care | 4 |
core vaccination | 4 |
months following | 4 |
diseases infectious | 4 |
recommended groups | 4 |
itp following | 4 |
cdv vaccines | 4 |
economic analysis | 4 |
among individuals | 4 |
mrna vaccines | 4 |
unpublished data | 4 |
global burden | 4 |
vaccine beginning | 4 |
aseptic meningitis | 4 |
causes serious | 4 |
step cluster | 4 |
canine influenza | 4 |
qualitative study | 4 |
following vaccines | 4 |
increased rate | 4 |
community members | 4 |
maternal vaccines | 4 |
killed product | 4 |
lymphocyte proliferation | 4 |
site vaccination | 4 |
adult pneumococcal | 4 |
preventive measure | 4 |
influenza outbreaks | 4 |
review committee | 4 |
care professionals | 4 |
combination vaccine | 4 |
free network | 4 |
increased prevalence | 4 |
powerful others | 4 |
flushing hospital | 4 |
asian countries | 4 |
current status | 4 |
vaccination response | 4 |
type hypersensitivity | 4 |
pharmaceutical industry | 4 |
many vaccine | 4 |
workers influenza | 4 |
home visits | 4 |
hospital employees | 4 |
preschool children | 4 |
york city | 4 |
containing adjuvants | 4 |
charlson comorbidity | 4 |
adjuvanted vaccines | 4 |
disease characterized | 4 |
recognition receptors | 4 |
biological warfare | 4 |
barre syndrome | 4 |
transmission model | 4 |
attenuated live | 4 |
previous research | 4 |
immunosuppressed patients | 4 |
targeted interventions | 4 |
itp cases | 4 |
porcine circovirus | 4 |
information sources | 4 |
sterile granulomas | 4 |
public understanding | 4 |
cdv vaccine | 4 |
medical interventions | 4 |
eff ect | 4 |
naturally acquired | 4 |
pertussis vaccines | 4 |
relatively small | 4 |
molecular patterns | 4 |
higher among | 4 |
encourage vaccination | 4 |
vary depending | 4 |
recent outbreak | 4 |
suspected adverse | 4 |
effi cacy | 4 |
social dual | 4 |
single dose | 4 |
travellers visiting | 4 |
population decision | 4 |
cats may | 4 |
will require | 4 |
fda approved | 4 |
last relapse | 4 |
quality assessment | 4 |
less effective | 4 |
following infection | 4 |
enforcement difficulties | 4 |
influenza type | 4 |
one person | 4 |
immunization education | 4 |
medical history | 4 |
conscientious objection | 4 |
per hcw | 4 |
national center | 4 |
disease infectious | 4 |
new program | 4 |
diseases caused | 4 |
may potentially | 4 |
efficacious vaccines | 4 |
based risk | 4 |
respondents reported | 4 |
planned behavior | 4 |
climate change | 4 |
also need | 4 |
heterogeneous networks | 4 |
behavioural control | 4 |
received vaccination | 4 |
different health | 4 |
two provisions | 4 |
incremental costs | 4 |
good example | 4 |
behaviour models | 4 |
influence vaccination | 4 |
bethyl laboratories | 4 |
adult population | 4 |
will get | 4 |
scientific basis | 4 |
studies found | 4 |
mitogen stimulation | 4 |
diseases preventive | 4 |
confirmed influenza | 4 |
travel purpose | 4 |
immediate veterinary | 4 |
vaccine protection | 4 |
heart disease | 4 |
developed world | 4 |
cerebrospinal fluid | 4 |
new developments | 4 |
occurs via | 4 |
last vaccination | 4 |
vaccines made | 4 |
polysaccharide vaccination | 4 |
antibody tests | 4 |
local levels | 4 |
viral shedding | 4 |
killed vaccine | 4 |
data regarding | 4 |
nurses branch | 4 |
chronic respiratory | 4 |
vaccines protective | 4 |
teriflunomide mg | 4 |
injection sites | 4 |
influenza transmission | 4 |
ensure high | 4 |
positive relation | 4 |
first step | 4 |
core feline | 4 |
two main | 4 |
using spss | 4 |
institutional review | 4 |
sirv model | 4 |
national recommendations | 4 |
well matched | 4 |
vaccine virus | 4 |
enzyme immunoassays | 4 |
older chinese | 4 |
following measles | 4 |
social justice | 4 |
care hospital | 4 |
induced immune | 4 |
initial puppy | 4 |
therapeutic jurisprudence | 4 |
virus recombinant | 4 |
risk following | 4 |
respiratory diseases | 4 |
street intercept | 4 |
following immunisation | 4 |
policy goals | 4 |
health regulations | 4 |
comparable installation | 4 |
registered nurses | 4 |
induce pneumonia | 4 |
autoimmune phenomena | 4 |
baseline characteristics | 4 |
eradication program | 4 |
vaccination recommendation | 4 |
health behavioural | 4 |
among healthy | 4 |
oral vaccine | 4 |
information regarding | 4 |
behavioral insights | 4 |
family member | 4 |
four times | 4 |
administered annually | 4 |
evolutionary dynamics | 4 |
diseases may | 4 |
staff members | 4 |
polysaccharide vaccines | 4 |
may arise | 4 |
trout olfactory | 4 |
disease pattern | 4 |
study influenza | 4 |
dog ownership | 4 |
antiviral use | 4 |
commonly used | 4 |
specific immune | 4 |
related adverse | 4 |
antiviral antibiotic | 4 |
economic burden | 4 |
quarantine laboratory | 4 |
preventing exposure | 4 |
arthritis patients | 4 |
immunity following | 4 |
physical distancing | 4 |
regular alcohol | 4 |
treatment policy | 4 |
social security | 4 |
cdv antibody | 4 |
may include | 4 |
interval ci | 4 |
tpb components | 4 |
practice guidelines | 4 |
area vaccination | 4 |
age followed | 4 |
platelet count | 4 |
specific effects | 4 |
national influenza | 4 |
spectrum disorder | 4 |
vaccination provides | 4 |
social influences | 4 |
appropriate tick | 4 |
catch influenza | 4 |
targeted vaccination | 4 |
lymphocyte subsets | 4 |
epidemic measures | 4 |
predominantly directed | 4 |
parvo vaccines | 4 |
vaccinations according | 4 |
different vaccination | 4 |
interventions aimed | 4 |
booster vaccination | 4 |
israeli parents | 4 |
relative vaccination | 4 |
vaccination intentions | 4 |
basic protein | 4 |
psychosocial factors | 4 |
ms relapses | 4 |
employee vaccination | 4 |
via fomites | 4 |
previous outbreak | 4 |
qualified nurses | 4 |
six papers | 4 |
communicable disease | 4 |
supportive care | 4 |
timely manner | 4 |
perception score | 4 |
optimal wellness | 4 |
highly recommended | 4 |
elimination efforts | 4 |
pelvic limb | 4 |
origin influenza | 4 |
exposure prophylaxis | 4 |
three groups | 4 |
retrospective cohort | 4 |
causing disease | 4 |
point likert | 4 |
sectional analysis | 4 |
vaccination resulted | 4 |
will lead | 4 |
pilot study | 4 |
air conditioning | 4 |
clinical personnel | 4 |
vaccine reactions | 4 |
protection provided | 4 |
factors include | 4 |
nonenveloped virus | 4 |
among amish | 4 |
topical product | 4 |
develop clinical | 4 |
comorbid condition | 4 |
enrolled nurses | 4 |
monthly income | 4 |
bad health | 4 |
papillomavirus vaccine | 4 |
must also | 4 |
vaccine hib | 4 |
among primary | 4 |
epidemiologic methods | 4 |
acute viral | 4 |
effector cells | 4 |
attenuated vaccine | 4 |
many people | 4 |
states vaccination | 4 |
study provides | 4 |
seroconversion rates | 4 |
economic status | 4 |
ventilation system | 4 |
northern territory | 4 |
common viral | 4 |
regression models | 4 |
diseases including | 4 |
patients must | 4 |
usually administered | 4 |
major concerns | 4 |
practitioner must | 4 |
mhc class | 4 |
health achievements | 4 |
main findings | 4 |
influenza activity | 4 |
superficial bladder | 4 |
decisions regarding | 4 |
vaccination series | 4 |
triennial vaccinations | 4 |
four months | 4 |
vaccine guidelines | 4 |
two vaccination | 4 |
fort dodge | 4 |
protection conferred | 4 |
randomized controlled | 4 |
following hbv | 4 |
dose schedule | 4 |
different antigens | 4 |
associated molecular | 4 |
hib vaccine | 4 |
local reactions | 4 |
research council | 4 |
employee health | 4 |
reverse transcriptase | 4 |
parenteral vaccine | 4 |
vaccines vaccines | 4 |
transmission also | 4 |
preventing infection | 4 |
individual animal | 4 |
subsequent vaccine | 4 |
strongly agreed | 4 |
omission bias | 4 |
vaccinations administered | 4 |
combined vaccine | 4 |
serologic response | 4 |
australian government | 4 |
virus may | 4 |
lacked influenza | 4 |
induce protective | 4 |
science foundation | 4 |
brief history | 4 |
may exhibit | 4 |
vaccination promotional | 4 |
incidence rate | 4 |
myelin basic | 4 |
mlv core | 4 |
owner concerns | 4 |
update rules | 4 |
among thai | 4 |
average number | 4 |
hemorrhagic septicemia | 4 |
giant cell | 4 |
marginalized populations | 4 |
positive results | 4 |
owned pets | 4 |
see later | 4 |
screening methods | 4 |
attitude towards | 4 |
financial sanction | 4 |
showed significantly | 4 |
twentieth century | 4 |
will allow | 4 |
first wave | 4 |
recommended immunization | 4 |
uenza vaccination | 4 |
study suggests | 4 |
younger adults | 4 |
vaccination intent | 4 |
vaccinate children | 4 |
population must | 4 |
muv genotypes | 4 |
active immune | 4 |
cfu ml | 4 |
convenient access | 4 |
vaccination policies | 4 |
health consequences | 4 |
financial penalty | 4 |
viral hemorrhagic | 4 |
major role | 4 |
effectiveness analysis | 4 |
vaccine response | 4 |
chronic illnesses | 4 |
longer able | 4 |
german hospital | 4 |